Clinical pharmacology of oxymorphone

Pain Medicine

Volumn 10, Issue SUPPL. 1, 2009, Pages

  Smith, Howard S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Absorption; Metabolism pharmacokinetic; Opioids; Oxymorphone; Pharmacodynamic excretion

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; MORPHINE; NALTREXONE; OPIATE; OXYMORPHONE; RIFAMPICIN;

ANALGESIC ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CONSTIPATION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; FOOD AND DRUG ADMINISTRATION; HUMAN; LIPOPHILICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NONHUMAN; PAIN; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 64249084148     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00594.x     Document Type: Review

References (48)

1. Endo Pharamceuticals. Oxymorphone Hydrochloride (Opana) Product Information. Chadds Ford, PA: Author; 2006.
2. Endo Pharamceuticals. Oxymorphone Hydrochloride, Extended-Release (Opana ER) Product Information. Chadds Ford, PA: Author; 2006.
3. Sinatra RS, Hyde NH, Harrison DM. Oxymorphone revisited. Semin Anesth 1998; 7: 209-15.
4. Eddy NB, Lee LEJ. The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxy-dihydromorphinon). J Pharmacol Exp Ther 1959; 125: 116-21.
5. Endo Pharmaceuticals. Data on File. Chadds Ford, PA: Author; 2003.
6. Beaver WT, Wallenstein SL, Houde RW, Rogers A. Comparisons of the analgesic effects of oral and intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 1997; 17: 186-98.
7. Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study. Curr Med Res Opin 2004; 20: 911-8.
8. Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study. Support Care Cancer 2005; 13: 57-65. Epub Nov 9, 2004.
9. Gallagher RM, Weiz-Bosna M, Gammaitoni A. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain. Pain Med 2007; 8: 71-4.
10. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended-release in chronic low back pain: Results of a randomized, double-blind, pkacebo- and active-controlled study. J Pain 2005; 6: 21-8.
11. Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ® ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, placebo-controlled study. J Pain 2007; 8: 175-84.
12. Katz N, Rauck R, Ahdieh H, Ma T. Gerritsen van der Hoop R, Kerwin R, Podolsky G. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naïve patients with chronic low back pain. Curr Med Res Opin 2007; 23: 117-28.
13. Kivitz A, Ma C, Ahdieh H, Galer B. A 2-week, multicenter, randomized, double-blind, placebo-controlled dose-ranging, phase III trial comparing the efficacy of oxymoprohone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther 2006; 3: 352-64.
14. Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005; 6: 357-66.
15. McIlwain H, Ahdieh H. Safety, tolerability, and effective ness of oxymorphone extended release for moderate to severe osteoarthritis pain: A one-year study. Am J Ther 2005; 12: 106-12.
16. Ananthan S, Khare NK, Saini SK, et al. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, and hydromorphone. J Med Chem 2004; 47: 1400-12.
17. Guay DR. Use of oxymorphone in the elderly. Consult Pharm 2007; 22: 417-30.
18. O'Neil MJ. The Merck Index, 13th edition. Whitehouse Station, NJ: Merck & Co.; 2001.
19. Poyhia R, Seppala T. Liposolubility and protein binding of oxycodone in vitro. Pharmacol Toxicol 1994; 74: 23-7.
20. Fand I, Sinatra R, Clouet D. Whole body autoradiographic localization of C[14]labeled morphine and nalorphine. Anat Rec 1978; 190: 392.
21. Drug facts and comparisons. 2006.
22. Alpharma. Kadian ® (Morphine Sulfate Sustained Release Capsules). Full Prescribing Information. Piscataway, NH: Author; 2004.
23. Purdue Pharma L.P. OxyContin® (Oxycodone Hydrochloride Extended-Release Capsules). Full Prescribing Information. Stanford, CT: Author; 2005.
24. Alpharma. OPANA ® ER (Oxymorphone HCI Controlled-Release Tablets). Full Prescribing Information. Piscataway, NJ: Author; 2004.
25. Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 1985; 62: 124-9.
26. Endo Pharmaceuticals Inc. OPANA ® (Oxymorphone Hydrochloride). Full Prescribing Information. Chadds Ford, PA: Author; 2007.
27. Cheng CY, Hsin LW, Lin YP, et al. N-cubylmethyl substituted morphinoids as novel narcotic antagonists. Bioorg Med Chem 1996; 4: 73-80.
28. Steinfels GF, Cook L. Antinociceptive profiles of Mu and Kappa opioid agonists in a rat tooth pulp stimulation procedure. J Pharmacol Exp Ther 1986; 236: 111-7.
29. American Hospital Formulary Service. Bethesda, MD: American Society of Health-System Pharmacists; 2006.
30. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, part I. Psychosomatics 2003; 44: 167-71.
31. Adams M, Pieniaszek HJ Jr, Gammanoni AR, et al. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 2005; 45: 337-45.
32. Cone EJ, Darwin WD, Buchwald WF, Gorodetzky CW. Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dogs. Drug Metab Dispos 1983; 11: 446-50.
33. Hashiguchi Y, Molina PE, Abumrad NN. Morphine-3-glucuronide: Hyperglycemic and neuroendocrine potentiating effects. Brain Res 1995; 694: 13-20.
34. Ulens C, Baker L, Ratka A, Waumans D, Tytgat J. Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies. Biochem Pharmacol 2001; 62: 1273-82.
35. Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand 1997; 41: 116-22.
36. Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: A pharmacotherapeutic review. J Opioid Manag 2008; 4: 131-44.
37. Adams MP, Ahdieh H. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs RD 2005; 6: 91-9.
38. Aqua K, Gimbel J, Singla N, etal. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abnormal surgery: A randomized, double-blind, active and placebo-controlled, parallel-group trial. Clin Ther 2007; 25: 1008-12.
39. Gimbel J, Ahdieh H. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg 2004; 99: 1472-7.
40. Thirlwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989; 63: 2275-83.
41. Leow KP, Smith MT, Watt JA, Williams BE, Cramond T. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 1992; 14: 479-84.
42. Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with caner. Clin Pharmacol Ther 1992; 52: 487-95.
43. Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: Results of a randomized crossover study. Pharmacotherapy 2004; 24: 468-76.
44. Barkin RI, Fusco AM, Barkin SJ. Opioids used in primary care for the management of pain: A pharamocologic, pharmacotherapeutic, and pharmacodynamic overview. In: Boswell MV, Cole BE, eds. Wieiner's Pain Management: A Practical Guide for Clinicians, 7th edition. New York: Taylor & Francis; 2006: 789-804.
45. Endo Pharmaceuticals Inc. Data on File. Chadds Ford, PA: Author; 2002.
46. Lee MA, Leng MEF, Cooper RM. Measurements of plasma oxycodone, noroxycodone, and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis. Pall Med 2005; 19: 259-60.
47. Cone EJ, Caplan YH, Moser F, Robert T, Black D. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol 2008; 32: 319-23.
48. McDonough PC, Levine B, Vorce S, Jufer RA, Fowler D. The detection of hydromorphone in urine specimens with high morphine concentrations. J Forensic Sci 2008; 53: 752-4.